Labiana Health, S.A. (BME:LAB)

Spain · Delayed Price · Currency is EUR

6.55

0.00 (0.00%)

Last updated: Aug 6, 2026, 4:07 PM CET

69.69% (1Y)

Market Cap	54.36M +100.0%
Revenue (ttm)	76.44M +13.5%
Net Income	2.57M +913.7%
EPS	0.37
Shares Out	8.30M
PE Ratio	17.93
Forward PE	8.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	354
Open	6.55
Previous Close	6.55
Day's Range	6.35 - 6.55
52-Week Range	3.64 - 8.20
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 21, 2026

About Labiana Health

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, the company offers contract developments, qua... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1958

Employees 373

Stock Exchange Madrid Stock Exchange

Ticker Symbol LAB

Full Company Profile

Financial Performance

In 2025, Labiana Health's revenue was 76.44 million, an increase of 13.46% compared to the previous year's 67.37 million. Earnings were 2.57 million, an increase of 913.67%.

Financial Statements